Back to search

Georgia Institute of Technology

Clinical utility of targeted RNAseq in neuromuscular and immune disorders

Abstract

dc:description.abstract

A specific genetic diagnosis leads to lower health care costs and improvement in clinical outcomes for rare congenital diseases. Despite significant advancements in sequencing technology and bioinformatic analysis, only about 35% of patients suspected of having a rare congenital disease receive a genetic diagnosis. Some of the main challenges facing WES and WGS are the interpretation of variants of uncertain significance (VUS) and accurately identifying and predicting the effect of potential splice variants. Recent research indicates RNA-seq can improve diagnostic yield for these disorders, but lack of standards for efficient analysis of RNA-seq data is a significant impediment to clinical implementation of functional assays for diagnosing rare disease. Through analysis of cohorts with neuromuscular disorders, primary immunodeficiencies, and inflammatory bowel disease, I show the clinical utility of RNA-seq and argue that my method of multi-faceted analysis in targeted RNA-seq outperforms whole transcriptome sequencing and any single tool developed for the identification of aberrant splicing.

Degree

thesis:*
Level thesis:degree_level
Doctoral
Department dc:contributor.department
Biology
Grantor dc:publisher
Georgia Institute of Technology
Year dc:date.issued
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Berger, Kiera

Subjects

dc:subject × 2

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1853/66645

Chain of custody

source
Harvested from
Georgia Tech
Base URL
repository.gatech.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Berger, Kiera. Clinical utility of targeted RNAseq in neuromuscular and immune disorders. Doctoral thesis, Georgia Institute of Technology, 2022. http://hdl.handle.net/1853/66645